Health care stocks were leaning lower premarket Friday with the Health Care Select Sector SPDR Fund (XLV) declining by 0.6% and the iShares Biotechnology ETF (IBB) down 1.1% recently.

Moderna (MRNA) shares were down more than 2% even after the company said the US Food and Drug Administration has approved its mRESVIA vaccine to prevent lower respiratory tract disease caused by respiratory syncytial virus in individuals aged 18 to 59 years who are at increased risk for disease.

BioCryst Pharmaceuticals (BCRX) shares were nearly 1% higher after the company said Colombia's National Institute of Drug and Food Surveillance has approved Orladeyo to prevent hereditary angioedema attacks in patients at least 12 years old.

Astria Therapeutics (ATXS) shares were up nearly 4% after the company said initial results from its ongoing long-term open-label trial of navenibart in hereditary angioedema showed a significant reduction in monthly attack rates, supporting the potential for dosing schedules of every three or six months.